BICO (formerly CELLINK) is a leading life science tools company offering life science tools that enable human organ and tissue production. By converging different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology; so called Bio Convergence, we enable our customers to improve people's health and lives for the better.
With a focus on the ecosystems of bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to print human tissues, perform high-throughput drug screening and develop new diagnostics solutions.
We create the future of life-saving treatments.
BICO has more than 25,000 instruments in the field and is entrusted by more than 3,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 10,000 publications. BICO is listed on Stockholm NASDAQ Large Cap under: BICO.